Quinoprazine_product_DataBase

Bioactivity	Quinoprazine is a potent inhibitor of Vaccinia virus DNA synthesis with an IC50 value of 10 μM. Quinoprazine has antimalarial activity against Plasmodium berghei and also displays antiprion potency, significantly decreases PrPSc levels[1]-[5].
Target	Vaccinia virus DNA synthesis
Invitro	Quinoprazine shows antimalarial action against Plasmodium berghei, the chloroquine-resistant isolate LN-K65[1].Quinoprazine blocks Vaccinia Virus infection by inhibiting DNA synthesis[2].Quinoprazine (IND2118) displays good antiprion potency and inhibits baseline PrPSc with reducing rates of 76% (dividing cells) and 51% (nondividing cells), respectively. Reducing PrPSc levels by >30% is considered to have good antiprion potency[3][4]. Quinoprazine (IND2118) shows low cytotoxicity with reducing rates of 25% (dividing cells) and 24% (nondividing cells), respectively. Reducing cells <30% is considered to have a safe effect[3][4].
In Vivo	Quinoprazine is a 1-alkyl-4-[4-(heterylamino)phenyl]piperazines derivate, Quinoprazine (0.25 g/kg; i.p.; single dose) suppresses the growth of larvocysts of Echinococcus multilocularis in cotton rats[5].Quinoprazine (0.2-0.5 g/kg; p.o.; single dose) acts against the adult Hymenolepis nana. Exptl. and cures infected mice radically[5].
Name	Quinoprazine
CAS	115618-99-0
Formula	C25H26N4
Molar Mass	382.50
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Mikhaĭlitsyn FS, et al. The search for new antiparasitic agents. 10. The synthesis, toxicological and antimalarial properties of nitrogen-containing heterocycles with a 4-(4-alkylpiperazinyl-1) phenylamine substituent (the preparation quinoprazine). Med P [2]. Ricciardi RP, et al. Therapeutic compounds for blocking DNA synthesis of POX viruses: United States, US20100035887[P]. 2010-02-11. [3]. Renslo AR, et al. Preparation of antiprion compounds containing thiazole-amine for treating neurodegenerative diseases: World Intellectual Property Organization, WO2013033037[P]. 2013-03-07. [4]. Silber BM, et al. Antiprion compounds that reduce PrP(Sc) levels in dividing and stationary-phase cells. Bioorg Med Chem. 2013 Dec 15;21(24):7999-8012. [5]. Mikhaĭlitsyn FS, et al. The search for new antiparasitic agents. 8. The synthesis and study of the acute toxicity, anti-alveolar hydatid and antihymenolepiasis activity of 1-alkyl-4[4-(heterylamino)phenyl]piperazines]. Med Parazitol (Mosk). 1991 Sep-Oct;(

PeptideDB

Quinoprazine

CAS: 115618-99-0 F: C25H26N4 W: 382.50